The American Urological Association has reserved a spot on its annual conference program for Dendreon Corp. (Nasdaq: DNDN) to present data from a late stage clinical trial of its prostate cancer treatment Provenge. Shares of the biotechnology company leaped $1.65 to close at $5.99.
AUA Reserves Spot For Dendreon At Annual Conference
April 03, 2009 at 16:56 PM EDT
